Filing Flows › Comparisons › AIM vs VIVS
AIM ImmunoTech vs VivoSim Labs: AIM and VIVS compared
AIM ImmunoTech is the larger company: $26K of revenue in its latest quarter (Q2 2026) against $18K for VivoSim Labs (Q1 FY27). AIM ImmunoTech is growing faster (+4% against -51% a year earlier).
Where the money goes: AIM and VIVS
AIM ImmunoTech (AIM) · Q2 2026
AIM ImmunoTech, Q2 2026: revenue $26K (+4% year over year), net loss $3.8M, operating cash flow −$4.6M. The chart follows the revenue to costs, profit and cash.
VivoSim Labs (VIVS) · Q1 FY27
VivoSim Labs, Q1 FY27: revenue $18K (-51% year over year), net loss $1.3M, operating cash flow −$3.2M. The chart follows the revenue to costs, profit and cash.
| AIM ImmunoTech (AIM) | VivoSim Labs (VIVS) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q1 FY27 |
| Revenue | $26K | $18K |
| Revenue growth, Y/Y | +4% | -51% |
| Operating margin | n/m | n/m |
| Net earnings | −$3.8M | −$1.3M |
| Operating cash flow | −$4.6M | −$3.2M |
Questions
Which is bigger, AIM ImmunoTech or VivoSim Labs?
AIM ImmunoTech is the larger company: $26K of revenue in its latest quarter (Q2 2026) against $18K for VivoSim Labs (Q1 FY27).
Is AIM ImmunoTech or VivoSim Labs growing faster?
AIM ImmunoTech is growing faster (+4% against -51% a year earlier).
More: AIM ImmunoTech earnings · how AIM ImmunoTech makes money · VivoSim Labs earnings · how VivoSim Labs makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 7, 2026; 10-Q filed Aug 12, 2026). Fiscal quarters can end on different dates. Not investment advice.